Pfizer CEO Is ‘Confident’ In Covid-19 Vaccine Rollout And Looking Beyond The Pandemic


At the 2020 Forbes Healthcare Summit, Albert Bourla is already looking beyond his company’s vaccine success and into a post-pandemic world.


Pfizer CEO Albert Bourla has accomplished in 11 months what usually takes years, with the company’s Covid-19 vaccine ready to hit the market in record time. Bourla told the 2020 Forbes Healthcare Summit he’s “confident” in the upcoming rollout and already looking towards future ways to apply the vaccine’s underlying technology. 

“We knew that the world needs this. We knew that we had to deliver. And we didn’t let any obstacles—and I can assure you there were many in our way—to stop us doing it,” Bourla told moderator Moira Forbes, president and publisher of ForbesWomen. His remarks came one day after Pfizer, along with its partner BioNTech, became the first companies in the world to get authorization for a Covid-19

Read More

Pfizer coronavirus vaccine approved for emergency use in UK: ‘Help is on the way’ | Health care/Hospitals

British officials authorized a COVID-19 vaccine for emergency use on Wednesday, greenlighting the world’s first shot against the virus that’s backed by rigorous science and taking a major step toward eventually ending the pandemic.

The go-ahead for the vaccine developed by American drugmaker Pfizer and Germany’s BioNTech comes as the coronavirus surges again in the United States and Europe, putting pressure on hospitals and morgues in some places and forcing new rounds of restrictions that have devastated economies.

The Medicines and Healthcare Products Regulatory Agency, which licenses drugs in the U.K., recommended the vaccine could be used after it reviewed the results of clinical trials that showed the vaccine was 95% effective overall — and that it also offered significant protection for older people, among those most at risk of dying from the disease. But the vaccine remains experimental while final testing is done.

“Help is on its way,” British

Read More

COVID-19: Approval of Pfizer vaccine is a historic moment for the UK | Science & Tech News, Reports

This is an historic moment. The beginning of the end of the pandemic. And it starts here in the UK, the first country to licence a COVID-19 vaccine.

The Pfizer/BioNTech jab was shown in clinical trials to prevent 95% of COVID cases. And it works just as well in the elderly, who are most at risk of serious illness from the virus.

With at least 59,000 deaths in the UK, 1.5 million worldwide, never has a vaccine been in greater need.

Live updates on coronavirus from UK and around world

The UK medical regulator has been reviewing data on safety and effectiveness as it came in from clinical trials in recent weeks, so it was able to give it the green light just a week after the companies formally applied for emergency use authorisation.

The first of 40 million doses – enough for 20 million people – will be shipped

Read More

Pfizer: A ‘New’ Growth Foundation In Genomic Medicine (NYSE:PFE)

Source: Finviz

“With the separation of Consumer Health last year and the expected separation of Upjohn later this year, we are significantly transforming our company. We are evolving from a diversified enterprise to a more focused and innovative biopharma company, from a scientific fast follower to a first-in-class scientific powerhouse. The transformation of this magnitude (began in 2010) could not happen within 1 or 2 years. The increased R&D productivity, as well as the depth and breadth of our pipeline, gave us the confidence to move so quickly over the past year to transform into the new Pfizer.

Albert Bourla Pfizer 2020 R&D Day

Pfizer (PFE) has a storied history dating back to its founding in 1849. Businesses do not thrive for over 170 years without redefining themselves, which is what Pfizer has done. The latest chapter was written in November when they spun off the Upjohn franchise. This followed

Read More

Pfizer vaccine refutes Trump’s nationalism, science attacks

Pfizer’s announcement that its COVID-19 vaccine is 95% effective has created significant optimism — except in the Trump camp, where adverse reactions of cynicism have emerged. His acolytes believe the press release was timed to prevent an injection of good news that might have secured reelection.

It is true that Pfizer’s CEO wanted to distance his scientists from the overt politics that would have come with taking Operation Warp Speed money. The company didn’t take funding but entered into an agreement to supply the United States with vaccine once the Food and Drug Administration approved. Trump’s adult children believe this pact was a result of their father’s deal-making prowess — but such supply agreements are quite common.

Whether the release was sat on and prevented a second term for Trump is likely never to be known. Regardless, Americans should feel relief because nothing about this vaccine is to his credit.

Read More

Pfizer and Moderna use mRNA in their COVID-19 vaccines. This never-before-used technology could transform how science fights diseases.

The success of two COVID-19 candidate vaccines marks a turning point in the long history of vaccines and could lead to major advances against a variety of diseases.

COVID-19 vaccine candidates from Moderna and Pfizer both promising

UP NEXT

UP NEXT

Vaccines developed by Pfizer/BioNTech and Moderna are more than 95% effective against COVID-19, trials show. Both depend on a technology never before used in a commercial vaccine that could upend the way future ones are made.

This new messenger RNA technology, as well another method that depends on viruses to deliver vaccines, are transforming the field, said Brendan Wren, a professor of vaccinology at the London School of Hygiene and Tropical Medicine.



a laptop computer sitting on top of a table: Pfizer's COVID-19 vaccine is being shipped in specially designed, insulated containers that hold between 195 and 975 five-dose vials and are about the size of a carry-on suitcase. The vials are stored in flat, pizza box-sized compartments, each of which holds 195 vials. A fully-loaded thermal container, which is reusable, contains five of these and weighs about 70 pounds. These "shippers" as Pfizer calls them have space at the top for dry ice, which can keep the vaccine at the necessary temperature for ten days if unopened, or five days as long as it’s opened no more than twice a day for very short periods of time


© Pfizer Inc.
Pfizer’s COVID-19 vaccine is being shipped in specially designed, insulated containers that hold between 195 and 975 five-dose vials and are about the size of a carry-on suitcase. The vials are stored in

Read More

Vaccine mRNA research from Moderna, Pfizer vs COVID huge for science

CLOSE

Pfizer and Moderna have both announced promising results in the phase 3 trials of their COVID-19 vaccines. Here’s how they differ.

Storyful

The success of two COVID-19 candidate vaccines marks a turning point in the long history of vaccines and could lead to major advances against a variety of diseases.

Vaccines developed by Pfizer/BioNTech and Moderna are more than 95% effective against COVID-19, trials show. Both depend on a technology never before used in a commercial vaccine that could upend the way future ones are made.

This new messenger RNA technology, as well another method that depends on viruses to deliver vaccines, are transforming the field, said Brendan Wren, a professor of vaccinology at the London School of Hygiene and Tropical Medicine.

“It could be quite a new era for vaccines and vaccinology,” he said. “We seemed to move ahead in this one year 10 years.”

These technologies had

Read More

Success of Pfizer, Moderna mRNA COVID-19 vaccines ushers in ‘new era’

CLOSE

Pfizer and Moderna have both announced promising results in the phase 3 trials of their COVID-19 vaccines. Here’s how they differ.

Storyful

The success of two COVID-19 candidate vaccines marks a turning point in the long history of vaccines and could lead to major advances against a variety of diseases.

Vaccines developed by Pfizer/BioNTech and Moderna are more than 95% effective against COVID-19, trials show. Both depend on a technology never before used in a commercial vaccine that could upend the way future ones are made.

This new messenger RNA technology, as well another method that depends on viruses to deliver vaccines, are transforming the field, said Brendan Wren, a professor of vaccinology at the London School of Hygiene and Tropical Medicine.

“It could be quite a new era for vaccines and vaccinology,” he said. “We seemed to move ahead in this one year 10 years.”

These technologies had

Read More

When Pfizer, Moderna vaccines could be available, and the genetic science behind how they work

In a year when every turn of the calendar brought more bad news, the recent announcements that two coronavirus vaccines are more than 90% effective is a rare shot of good news.

Moderna and Pfizer both revealed promising results this month for the mRNA vaccine candidates both companies are developing.

Moderna, which worked with scientists from the National Institutes of Health, said Monday its vaccine was 94.5% effective against SARS-CoV-2 and the disease it causes, COVID-19. Last week Pfizer and BioNTech said preliminary results show its COVID-19 vaccine is 95% effective.

For this week’s FAQ Friday, we answer questions about COVID-19 vaccines, the findings of which have not yet been peer-reviewed.

When will the vaccines be available?

Pfizer said Friday it applied to the Food and Drug Administration (FDA) for emergency authorization for its vaccine. The FDA and an independent committee will then make a recommendation. Moderna is expected to

Read More

‘A special day’: End of Pfizer trial paves way for a COVID shot this year

Sign up for our COVID-19 newsletter to stay up-to-date on the latest coronavirus news throughout New York City

(Reuters) – Final results from Pfizer Inc’s <PFE.N> COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday.

The efficacy rate of the vaccine developed by Pfizer and its German partner BioNTech <BNTX.O> is the highest of any candidate in late-stage clinical trials so far, and experts said it was a significant achievement in the race to end the pandemic.

Pfizer said 170 volunteers in its trial involving over 43,000 people contracted COVID-19 but 162 of them had only been given a placebo, meaning the vaccine was 95% effective. Of the 10 people who had severe COVID-19, one had received the vaccine.

“A first in the

Read More